212 related articles for article (PubMed ID: 17400953)
1. Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge.
Kotlyar M; Mendoza-Baumgart MI; Li ZZ; Pentel PR; Barnett BC; Feuer RM; Smith EA; Hatsukami DK
Tob Control; 2007 Apr; 16(2):138-42. PubMed ID: 17400953
[TBL] [Abstract][Full Text] [Related]
2. Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine.
Mendoza-Baumgart MI; Tulunay OE; Hecht SS; Zhang Y; Murphy S; Le C; Jensen J; Hatsukami DK
Nicotine Tob Res; 2007 Dec; 9(12):1309-23. PubMed ID: 18058349
[TBL] [Abstract][Full Text] [Related]
3. Nicotine delivery, cardiovascular profile, and subjective effects of an oral tobacco product for smokers.
Blank MD; Sams C; Weaver MF; Eissenberg T
Nicotine Tob Res; 2008 Mar; 10(3):417-21. PubMed ID: 18324559
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers.
Cobb CO; Weaver MF; Eissenberg T
Tob Control; 2010 Oct; 19(5):367-73. PubMed ID: 19346218
[TBL] [Abstract][Full Text] [Related]
5. Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology.
Gray JN; Breland AB; Weaver M; Eissenberg T
Nicotine Tob Res; 2008 Sep; 10(9):1441-8. PubMed ID: 19023835
[TBL] [Abstract][Full Text] [Related]
6. Timing of nicotine lozenge administration to minimize trigger induced craving and withdrawal symptoms.
Kotlyar M; Lindgren BR; Vuchetich JP; Le C; Mills AM; Amiot E; Hatsukami DK
Addict Behav; 2017 Aug; 71():18-24. PubMed ID: 28235705
[TBL] [Abstract][Full Text] [Related]
7. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.
Shiffman S
Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988
[TBL] [Abstract][Full Text] [Related]
8. Evaluating oral noncombustible potential-reduced exposure products for smokers.
Blank MD; Eissenberg T
Nicotine Tob Res; 2010 Apr; 12(4):336-43. PubMed ID: 20159791
[TBL] [Abstract][Full Text] [Related]
9. Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study.
Kotlyar M; Hertsgaard LA; Lindgren BR; Jensen JA; Carmella SG; Stepanov I; Murphy SE; Hecht SS; Hatsukami DK
Cancer Epidemiol Biomarkers Prev; 2011 Jan; 20(1):91-100. PubMed ID: 21068204
[TBL] [Abstract][Full Text] [Related]
10. Oral tobacco products: preference and effects among smokers.
Hatsukami DK; Jensen J; Anderson A; Broadbent B; Allen S; Zhang Y; Severson H
Drug Alcohol Depend; 2011 Nov; 118(2-3):230-6. PubMed ID: 21515003
[TBL] [Abstract][Full Text] [Related]
11. Acceptability and effectiveness for withdrawal symptom relief of a novel oral nicotine delivery device: a randomised crossover trial.
Shahab L; McEwen A; West R
Psychopharmacology (Berl); 2011 Jul; 216(2):187-96. PubMed ID: 21318563
[TBL] [Abstract][Full Text] [Related]
12. A pilot randomized study of smokeless tobacco use among smokers not interested in quitting: changes in smoking behavior and readiness to quit.
Carpenter MJ; Gray KM
Nicotine Tob Res; 2010 Feb; 12(2):136-43. PubMed ID: 20053788
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of moist snuff in humans.
Fant RV; Henningfield JE; Nelson RA; Pickworth WB
Tob Control; 1999; 8(4):387-92. PubMed ID: 10629244
[TBL] [Abstract][Full Text] [Related]
14. Potential reduction exposure products and FDA tobacco and regulation: a CNS call to action.
Heath J; Andrews J; Balkstra CR
Clin Nurse Spec; 2004; 18(1):40-8; quiz 49-50. PubMed ID: 15061445
[TBL] [Abstract][Full Text] [Related]
15. A randomized clinical trial of nicotine lozenge for smokeless tobacco use.
Ebbert JO; Severson HH; Croghan IT; Danaher BG; Schroeder DR
Nicotine Tob Res; 2009 Dec; 11(12):1415-23. PubMed ID: 19880578
[TBL] [Abstract][Full Text] [Related]
16. The effect of acute exercise on cigarette cravings while using a nicotine lozenge.
Tritter A; Fitzgeorge L; Prapavessis H
Psychopharmacology (Berl); 2015 Jul; 232(14):2531-9. PubMed ID: 25701265
[TBL] [Abstract][Full Text] [Related]
17. Nicotine delivery and subjective effects of Swedish portion snus compared with 4 mg nicotine polacrilex chewing gum.
Lunell E; Curvall M
Nicotine Tob Res; 2011 Jul; 13(7):573-8. PubMed ID: 21454913
[TBL] [Abstract][Full Text] [Related]
18. Randomized Trial to Compare Smoking Cessation Rates of Snus, With and Without Smokeless Tobacco Health-Related Information, and a Nicotine Lozenge.
Nelson PR; Chen P; Battista DR; Pillitteri JL; Shiffman S
Nicotine Tob Res; 2019 Jan; 21(1):88-94. PubMed ID: 29373698
[TBL] [Abstract][Full Text] [Related]
19. Effect of nicotine lozenge use prior to smoking cue presentation on craving and withdrawal symptom severity.
Kotlyar M; Vogel RI; Dufresne SR; Mills AM; Vuchetich JP
Drug Alcohol Depend; 2020 Jan; 206():107706. PubMed ID: 31757519
[TBL] [Abstract][Full Text] [Related]
20. A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics.
Walele T; Sharma G; Savioz R; Martin C; Williams J
Regul Toxicol Pharmacol; 2016 Feb; 74():187-92. PubMed ID: 26696273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
